Compare ADMA Biologics Inc (ADMA) vs Alphabet Inc Class A (GOOGL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Alphabet Inc Class A — how do they compare? ADMA Biologics Inc trades at $9.26 (market cap $2.13B), while Alphabet Inc Class A trades at $359.07 (market cap $4.46T). The key difference: Alphabet Inc Class A is far larger — about 2093.9× ADMA Biologics Inc's market cap, and Alphabet Inc Class A pays a 0.24% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | GOOGL | |
|---|---|---|
Market Cap | $2.13B | $4.46T |
Sector | Health | Media |
52-Week High | $20.38 | $402.62 |
52-Week Low | $7.60 | $174.36 |
Enterprise Value | $2.20B | $4.42T |
Dividend Yield | — | 0.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Alphabet (GOOGL) trades at $358.85, down 2.08% today, with a bullish technical outlook supported by moving averages. The company reported strong earnings beats in recent quarters, including Q1 2026 EPS of $5.11 versus $2.64 expected. Revenue grew to $402.84 billion in 2025, with net income margins expanding to 32.8%. Analyst consensus remains overwhelmingly positive, with 85% buy ratings and a $431.35 price target.
GOOGL presents a compelling growth story driven by AI integration and cloud expansion, though regulatory scrutiny and competitive pressures pose risks. The stock's valuation at 28 times earnings is justified by robust profitability and cash flow generation. Upside potential exists if execution continues, but investors should monitor antitrust developments and tech sector volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Alphabet Inc Class A
Alphabet, the parent company of Google, earns nearly 90% of its revenue from Google services, mainly through advertising. Other revenue comes from subscriptions (YouTube TV, YouTube Music), platform sales (Play Store purchases), and devices (Pixel, Chromebooks, Chromecast). Google Cloud contributes around 10%, while investments in self-driving cars (Waymo), health (Verily), and internet access (Google Fiber) make up the rest.
Read more on GOOGL →
